[HTML][HTML] An update on oral drug delivery via intestinal lymphatic transport

Z Zhang, Y Lu, J Qi, W Wu - Acta Pharmaceutica Sinica B, 2021 - Elsevier
Z Zhang, Y Lu, J Qi, W Wu
Acta Pharmaceutica Sinica B, 2021Elsevier
Orally administered drug entities have to survive the harsh gastrointestinal environment,
penetrate the enteric epithelia and circumvent hepatic metabolism before reaching the
systemic circulation. Whereas the gastrointestinal stability can be well maintained by taking
proper measures, hepatic metabolism presents as a formidable barrier to drugs suffering
from first-pass metabolism. The pharmaceutical academia and industries are seeking
alternative pathways for drug transport to circumvent problems associated with the portal …
Abstract
Orally administered drug entities have to survive the harsh gastrointestinal environment, penetrate the enteric epithelia and circumvent hepatic metabolism before reaching the systemic circulation. Whereas the gastrointestinal stability can be well maintained by taking proper measures, hepatic metabolism presents as a formidable barrier to drugs suffering from first-pass metabolism. The pharmaceutical academia and industries are seeking alternative pathways for drug transport to circumvent problems associated with the portal pathway. Intestinal lymphatic transport is emerging as a promising pathway to this end. In this review, we intend to provide an updated overview on the rationale, strategies, factors and applications involved in intestinal lymphatic transport. There are mainly two pathways for peroral lymphatic transport—the chylomicron and the microfold cell pathways. The underlying mechanisms are being unraveled gradually and nowadays witness increasing research input and applications.
Elsevier
以上显示的是最相近的搜索结果。 查看全部搜索结果